Why the study?
PRKAG2 syndrome can mimic hypertrophic cardiomyopathy with high arrhythmogenic risk, posing diagnostic and therapeutic challenges.
PRKAG2 syndrome should be considered in the differential diagnosis of hypertrophic cardiomyopathy, especially given its high risk of malignant arrhythmias and conduction disorders.
Consider PRKAG2 testing in atypical HCM with extracardiac features; leaves open whether expanded panels improve diagnosis or outcomes.
HypertrofickĂĄ kardiomyopatie (HKMP) postihuje 0,2 % populace a pĹedstavuje nejÄastÄjĹĄĂ formu dÄdiÄnĂŠho onemocnÄnĂ srdeÄnĂho svalu u dospÄlĂ˝ch. NejÄastÄjĹĄĂ pĹĂÄinou HKMP jsou zmÄny v genech kĂłdujĂcĂch proteiny sarkomery. AĹž 10 % pacientĹŻ je vĹĄak postiĹženo jinĂ˝m typem systĂŠmovĂŠho genetickĂŠho onemocnÄnĂ, kterĂŠ mĂĄ hypertrofii myokardu pouze jako jeden ze svĂ˝ch multiorgĂĄnovĂ˝ch projevĹŻ. Mezi tato onemocnÄnĂ patĹĂ i glykogenĂłza PRKAG2, stĹĂĄdavĂŠ onemocnÄnĂ zpĹŻsobenĂŠ dÄdiÄnĂ˝m defektem γ2 regulaÄnĂ podjednotky proteinkinĂĄzy aktivovanĂŠ adenosin monofosfĂĄtem (AMPK). Ta kromÄ myopatie kosternĂch svalĹŻ zpĹŻsobuje i HKMP s vysokĂ˝m rizikem malignĂch komorovĂ˝ch i sĂĹovĂ˝ch arytmiĂ a Ĺadu pĹevodnĂch poruch. DĂky ĂşzkĂŠ spoluprĂĄci nÄkolika pracoviĹĄĹĽ jsme diagnostikovali dvÄ rodiny s pĹĂÄinnou variantou DNA v genu PRKAG2. Na podkladÄ prezentovanĂ˝ch kazuistik dokumentujeme velmi variabilnĂ projevy syndromu PRKAG2, a upozorĹujeme tak na ĂşskalĂ v jeho klinickĂŠ diagnostice i terapii. © 2023, ÄKS.
No takes yet. Share an insight, caveat, or question.
Hodboďová et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: